OUR PROVIDERS

Thomas D. Wooldridge, M.D.

Thomas D. Wooldridge, M.D.


EDUCATION


GRENADA HIGH SCHOOL
Grenada, MS; 1964

MILLSAPS COLLEGE
Jackson, MS; 1964 – 1968; Degree – B.A. Chemistry & B.S. Biology

UNIVERSITY OF MISSISSIPPI MEDICAL CENTER
Jackson, MS; 1972; Degree – M.D.


INTERNSHIP


UNIVERSITY HOSPITAL OF JACKSONVILLE
Jacksonville, FL; 1972 – 1973; Internal Medicine


RESIDENCY


UNIVERSITY OF MISSISSIPPI MEDICAL CENTER
Jackson, MS; 1973 – 1975; Internal Medicine

VETERANS ADMINISTRATION HOSPITAL
Jackson, MS; 1973 – 1975; Internal Medicine


FELOWSHIP


CLINICAL FELLOW IN NEPHROLOGY
University of Mississippi Medical Center; Jackson, MS; 1975 – 1976

CLINICAL RESEARCH FELLOW
University ofMississippi Medical CenJackson, MS; 1976 – 1977


BOARD CERTIFICATION


Mississippi State Board of Medical Examiners; 1972

American Board of Internal Medicine; 1975

American Board of Internal Medicine – Subspecialty of Nephrology; 1978


PROFESSIONAL HISTORY


PRACTICE OF NEPHROLOGY AND DIRECTOR OF ARTIFICIAL KIDNEY UNIT
North Mississippi Medical Center; Tupelo, MS 1977 – Present


ACTIVITIES AND ORGANIZATIONS


Mississippi State Medical Association

Mississippi Nephrologic Society – President   1994-1995

Mississippi Kidney Foundation

American Medical Association

American Society of Nephrology

International Society of Nephrology

Renal Physicians Association

Northeast Mississippi Academy of Internal Medicine

Northeast Mississippi Kidney Foundation – Medical Advisor

Listed in “Best Doctors In America” 1995

Network 8 – Medical Review Board; 1997 – 2003; 1999 – 2003 – Chairman; 2007 – present – Chairman

Member HCFA Forum – 1999 to 2003

Renal Care Group Medical Advisory Board 2002-2006

Fresenius Regional Medical Advisory Board 2007 – present

Fresenius Corporate Medical Advisory Board 2007 – present

Mississippi Task Force for Nephrology 2011-present

Chief of Nephrology section-leader 2011-present


PUBLICATIONS


Wooldridge, Thomas D., Bower, John D., Holbert, Robert D., and Ruvinsky, Marcelo J.:  LeVeen Shunt (LS):  Long Term Therapy for Idiopathic Ascites of Chronic Renal Failure.  Proc. of Clinical Dialysis and Transplant Forum, November, 1976. Clinical Dialysis and Transplant Forum, November, 1976.

Ruvinsky, Marcelo J., Holbert, Robert D., Bower, John D., and Wooldridge, Thomas D.:  Peritoneal Dialysis:  A Review.  The Journal of the Mississippi State Medical Association, May, 1977.

Wooldridge, Thomas D., Bower, John D.:  Rhabdomyolysis As A Complication of Parathyroidectomy and Calcium Supplementation. The Journal of the Mississippi State Medical Association, 239: 643, February 13, 1978.

Wooldridge, Thomas D.:  Presenting the Options of Dialysis at North Mississippi Medical Center.  Dialysis and Transplantation 11:1048, December, 1982.

Wooldridge, Thomas D., and Cox, John W.:  Graft Infection and Bacteremia. Archives of Internal Medicine, 143:1070, May, 1983.

Wyatt, Robert H., Valenski, William R., Stapleton, R. Bruder, Roy, Shane, III, Wooldridge, Thomas D., Trouy, Robert L., and Herrod, Henry G.:  Immunoregulatory Studies in Patients with IgA Nephropathy.  J.Clin.Lab.Immunol.  (1988), 25, 109-114.

Wooldridge, Thomas D.: Growing the Home Program – How We Did It. Fresensius Medical Directors Symposium 2007

Nasr, Samih H.; Milliner, Dana S.; Wooldridge, Thomas D.; Sethi, Sanjeev. Triamterene Crystal Nephropathy. American Journal of Kidney Disease, 63:1,148-152, January 2014


ABSTRACTS


Ruvinsky, Marcelo J., Holbert, Robert D., Bower, John D., Bostwick, Hines, and Wooldridge, Thomas D.:  Thomas D.:  Renal Failure as Primary Manifestation of Sarcoidosis.  The American Society for Artificial Internal Organs, San Francisco, California meeting, April, 1976.

Wooldridge, Thomas D., Bower, John D., Holbert, Robert D., and Ruvinsky, Marcelo J.:  LeVeen Shunt (LS): Long Term Therapy for Idiopathic Ascites of Chronic Renal Failure.  Clinical Dialysis and Transplant Forum, Washington, D.C., November, 1976.

Holbert, Robert D., Wooldridge, Thomas D., Ruvinsky, Marcelo J., and Bower, John D.:  Effects of Ultrafiltration in Hemodialysis Without Dialysate.  Clinical Dialysis and Transplant Forum, Washington, D.C., November, 1976.

Wooldridge, T.D., Holbert, R.D., Bower, J.D., Bostwick, Hines, and Ruvinsky, M.J.: Sarcoidosis as a Reversible Cause of  Apparent End Stage Renal Disease.  American College of Physicians, 58th Annual Session, Dallas, Texas, April 1977.

Wooldridge, T.D. and Bower, John D.:  Non-Operative Treatment of Retroperitoneal Fibrosis.  The American Society of Nephrology, 10th Annual Meeting, Washington, November, 1977.

Rudman, William, Ph.D.; Wooldridge, Tom, M.D.; Thornton- Hartzog, Cathy, MHS, BSN, RN, CNN; McElroy, Rosemary, BSN, RN, CNN; Dyson, Brenda; Kennedy, Michael; Fuller, Jerry: Examining Factors Related to Successful Dialysis of ESRD   Patients: The Story Behind the Numbers.  HCFA & Forum of ESRD Networks Annual Meeting, Baltimore, Maryland, June, 2001.

Thornton-Hartzog, Cathy, MHS, BSN, RN, CNN; Rudman, William, Ph.D.; Fuller, Jerry; McElroy, Rosemary, BSN, RN, CNN; Dyson, Brenda; Wooldridge, Thomas, M.D.:  Improving Hemodialysis Adequacy in Network 8.  CMS/Forum of ESRD Networks Annual Meeting, Baltimore, Maryland, March, 2002.

Wooldridge, Thomas D, M.D.; Kaplan, Mark; Alcorn, Harry W.; Mulivor, Aaron W.;  Smith, William T.: The Pharmacokinetics and Safety of a Single Dose of Sotatercept in Subjects on Hemodialysis and the Effects of its Murine Analog on Anemia and in Preventing Bone Loss in C57BL/6 Mice with 5/6 Nephrectomy. The American Society of Nephrology, Kidney Week 2012, November 2012.

El-Shahawy, Mohamed; Cotton, James; Kaupke, Jeffrey; Wooldridge, Thomas, M.D.; Singh, Hem; Smith; William: Interim Analysis of ACE-011-REN-001:The First 28-day Dose Cycle of Low and Medium Starting Doses of Sotatercept Compared to Placebo for Correction of Anemia in Hemodialysis Subjects. Presented at  National Kidney Foundation 2014 Spring Clinical Meeting, Las Vegas, NV, April 22-26, 2014.

El-Shahawy, Mohamed; Cotton, James; Kaupke, Jeffrey; Wooldridge, Thomas, M.D.; Smith; William: Long Term Effects of Sotatercept Compared with Placebo for Correction of Anemia in Hemodialysis Subjects: Interim Analysis of ACE-011-REN001 Phase 2A Study. Presented at EDTA Congress, June 1, 2014, Amsterdam.

Wooldridge, Thomas, M.D.; Efficiency and Safety of Iron-Based Phosphate Binder Sucroferric Oxylhydroxide in CKD Patients on Peritoneal Dialysis or Hemodialysis. Presented at the Annual Dialysis Conference, New Orleans, LA, February 2, 2015.

 Amburzs, Josephine M.; Beck, Lawrence H; Coles, Paige A; Collins, A. Bernard; Colvin, Robert B.; Cossey, Nicholas; Klein, Jon B.; Larsen, Christopher P.; Hong, Ma; Merchant, Michael; Messias, Nidis Cordeiro; Rosales, Ivy A; Salent, David J.; Trivio-Dvillach, Claire; Walker, Patrick D; Wilkey, Daniel W.; Wooldridge, Thomas D.: Low-Density Lipoprotein Receptor Related 2 (Megalin) as Target.

Antigen in Human Kidney Anti-Brush Border Antibody Disease. Presented at the American Society of Nephrology Annual Meeting, New Orleans, LA, October 31, 2017

Devita, Maria V; Gandhi, Nirav; Lyer, Sriram, Kjawas, Osma S; Kopyt, Nelson P; Lee, Joseph J; Lynn, Robert I; Paulson, William D; Wooldridge, Thomas D: Six Month AV Fistula Outcomes Following Local Perianastomotic Delivery of Sirolimus Preliminary Report from a US Phase 3 Clinical Trial (ACCESS TRIAL)

29 (2): 644-653 LDL Receptor-Related Protein 2 (Megalin) as a Target Antigen in Human Kidney Anti-Brush Border Antibody Disease. Christopher P. Larsen; Claire Trivin-Avillach; Thomas D. Wooldridge; Lawrence H. Beck

Sirolimus Treated AV Fistula; Maturation Profile and Impact of Process of Care Presented at 2018 ASN- San Diego, CA. Sriram Iyer; Nelson Kopyt; Nirav Ghandi; Naveen K Atray; Thomas D. Wooldridge; Joseph Lee; Kendrra S. Herndon.

Arteriovenous Fistula Maturation Outcome Following Local Perianastomatic Delivery of Sirolimus. Presented at 2018 ASN- San Diego, CA. Sriram Iyer; Nelson Kopyt; Nirav Ghandi; Naveen K Atray; Thomas D. Wooldridge; Joseph Lee; Kendrra S. Herndon.

Wooldridge, TD; McCafferty, K; Schoemig, M, et al: Efficacy and Safety of Difelikefalin for moderate to severe CKD associated pruritus. A global phase 3 study in hemodialysis patients. (KALM-2). Presented at Kidney Week 2020 Reimagined October 19-25, 2020. Abstract FR-OR24.

Cahill, M; Fishbaub S; Wooldridge, T; Wen W; Munera C; Menzaghi F. Improvements in itch-related quality of life with difelikefalin for moderate to severe chronic kidney disease-associated pruritus. Pooled results of KALM-1 and KALM-2 phase 3 studies in hemodialysis patients poster presentation at the virtual 2021 American Nephrology Nurses Association National Symposium, May 2-5, 2021.

Efficacy of Difelikefalin for the treatment of moderate to severe pruritis in hemodialysis patients. Pooled analysis of KALM-1 and KALM-2 phase 3 studies. Topf, Joel; Wooldridge, Thomas; McCafferty, Keran; et al: Published in Kidney Medicine June 28, 2022

Inaxaplin for proteinuric kidney disease in persons with two APOL1 variants. New England Journal of Medicine, 2023 March 16, 388 (11) 969-979. Egbuna, Ogo; Zimmerman, Brandon; et al. Collaborators: Aqeel, Ahmed; Wooldridge, Thomas.

Novel Renal Autologous Cell Therapy (REACT) for chronic kidney disease with diabetes (DKD Investigative Trial Experience in Mississippi). Rippee, D; Wooldridge, Thomas; Dossabhoy, N; Butram, Alicia; Christian, Diana; Daigle, T; and Stavas, J. Presented at the National Kidney Foundation Spring Clinical Meetings. Austin, TX April 10-15, 2023.

CONTACT INFORMATION 

TUPELO, MS LOCATION

1542 MEDICAL PARK CIRCLE, TUPELO, MS 38801

PHONE: 662-844-4711   |   FAX: 662-844-9619

TOLL FREE: 1-866-344-4711

OXFORD, MS LOCATION

1790 BARRON STREET, OXFORD, MS 38655

PHONE: 662-236-2900   |   FAX: 662-236-2922